1. Home
  2. AKTX vs LITB Comparison

AKTX vs LITB Comparison

Compare AKTX & LITB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

N/A

Current Price

$9.88

Market Cap

15.4M

Sector

Health Care

ML Signal

N/A

LITB

LightInTheBox Holding Co. Ltd.

N/A

Current Price

$3.07

Market Cap

57.1M

ML Signal

N/A

Company Overview

Basic Information
Metric
AKTX
LITB
Founded
N/A
2007
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
15.4M
57.1M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
AKTX
LITB
Price
$9.88
$3.07
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$33.50
N/A
AVG Volume (30 Days)
77.2K
5.6K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$14.50
Revenue Next Year
N/A
$11.59
P/E Ratio
N/A
$10.96
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$1.63
52 Week High
$29.32
$4.17

Technical Indicators

Market Signals
Indicator
AKTX
LITB
Relative Strength Index (RSI) 53.55 45.69
Support Level $9.20 $2.82
Resistance Level $15.50 $3.34
Average True Range (ATR) 1.30 0.18
MACD 0.14 -0.01
Stochastic Oscillator 54.76 13.51

Price Performance

Historical Comparison
AKTX
LITB

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

About LITB LightInTheBox Holding Co. Ltd.

LightInTheBox Holding Co Ltd is a e-commerce company, providing a diverse range of affordable lifestyle products directly to consumers. Its brands include Ador, a women's fashion brand targeting women aged 35-55; the second is a golf apparel brand focusing on female golfers aged 35 and above; the third is a women's light party dress brand for the age group of 30 and above. It offers customers products through websites and mobile applications. The company operates and reviews its performance in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of the provision of logistic services to companies and individual customers.

Share on Social Networks: